- Contraception For Teens: Let's Talk About It
- Gounder Gives Lowdown on Ebola, Peptides, and Colorectal Screenings
- ASCO: Pfizer one-ups J&J with Talzenna combo's broad castration-sensitive prostate cancer win
- ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL
- 6 dental technology updates in May
- From clinician to leader: Building confidence, capability and leadership in dentistry
- Operationalizing AI at scale: A practical framework for enterprise-scale success
- 3 key stats on the orthodontist workforce
- Meet the COOs of 10 specialty DSOs
- Data, cross-training, and pipeline development: How health systems are rethinking OR staffing
- How top health systems are redefining the digital patient experience
- ‘The most significant change in 20 years’: Cancer centers prepare for daraxonrasib demand
- A Smooth Handoff From Decision to Dollars: Connecting the Last Mile in Healthcare Payments
- Budget-Strapped Montana Will Stress-Test Trump’s Medicaid Work Rules
- How CEOs actually use hospital rankings — and when they don’t
- What OU Health’s founding CEO learned building a new health system
- Arkansas hospital CEO to step down after 11 years for new role
- The behavioral health workforce pipeline: Where it stands and where it’s headed
- 6 major investments in youth behavioral health
- Coalition for Health AI unveils governance playbook for systems
- 66 health systems ranked by long-term debt
- UnitedHealthcare drops some prior auth requirements for cardiology, orthopedic services
- 8 No Surprises Act shake-ups physicians need to know
- The ASC independence playbook: 3 leaders’ thoughts
- Dr. Rahimah Maina opens new dental practice
- GWU offloaded its $450M physician group problem — why the industry watching
- The gastroenterologist pay gap
- Texas surgery center to double in size, add 2 ORs
- What dental leaders told us in May
- Climate Change: Statement on Proposed Rescission of Climate-Related Disclosure Rules
- Kenyan Court Blocks Trump's Plan To Quarantine Ebola Patients
- What’s going on at the FTC? 3 notes for ASC leaders
- 8 DSOs making headlines
- The physician noncompete battle in 5 key figures
- The physician red flags that can predict a bad ASC partner
- Patient death draws renewed CMS scrutiny at HCA’s Mission Hospital
- Nearly 70% of US counties lack a GI: 13 concerning workforce stats
- Statement of Commissioner Mark T. Uyeda on the Rescission of Climate-Related Disclosure Rules
- A new behavioral health profession is born
- Keynote Remarks at the 2026 Reagan National Economic Forum
- Statement on Proposing Release for Rescission of Climate-Related Disclosure Rules
- Dentists’ pay climbed the most in these 10 states
- Mental Health Disorders Now No. 1 Cause of Disability Worldwide
- Massachusetts AG sues UnitedHealthcare over alleged Medicaid fraud
- UnitedHealthcare to nix nearly two thirds of pediatric prior auths
- Industry Voices—Patients are building a new healthcare system. The industry is finally catching up
- Weekly Rundown—Moffitt Cancer Center expands Reimagine Care's virtual oncology model; Tanner Health deploys AI workforce solution
- Study: LA Canine Outbreak Caused By Low Vaccination Rates, Crowded Boarding
- Ocrelizumab Effective In Slowing Progressive MS, Trial Shows
- Long COVID Might Be Twice As Common As Previously Thought
- In Vaccine-Skeptical California County, A Potential Playbook To Contain Measles
- Heavy Drinking Harms College Students' Brain Power, Study Finds
- A Trump Stronghold Grapples With Health Risks of ICE Detention Sites
- After Her Bout of Amnesia, a $59,000 Billing Dispute Wouldn’t Go Away
- Pharma urged to modernize patient support as young adult cancer rates rise
- Philips adds a spoonful of Disney sugar to ease kids’ MRI anxieties
- MannKind seeks long-awaited sales boost with inhaled insulin approval for kids
- Aetna to launch ‘on demand’ virtual mental health services in 2027
- U of Connecticut dental school reappoints dean for 2nd term
- Michigan dentist charged with Medicaid fraud
- Brand-name drug prices climb after launch in US, fall abroad amid MFN push: report
- ASCO: After Takeda’s defeat, Dizal picks up baton to take on J&J in EGFR lung cancer subtype
- Acadia in the headlines: 6 things to know
- 26 behavioral health executive moves to know
- AstraZeneca gains 2nd bladder cancer nod in key expansion for Imfinzi
- Advocate Health grows Q1 revenue by 10.8% amid higher volumes, greater efficiency
- Behavioral health hospital operator to pay $32M in Medicare fraud settlement
- Bangladesh Measles Surge Kills 500+ Children; Vaccine Delays Blamed
- Care navigation startup Garner Health banks $100M series E at $2.74B valuation
- HCA bolsters workforce pipeline with healthcare professional college acquisition
- Plant-Based Diet May Cut Obesity Risk For Women In Menopause
- Pharma leaders meet with PM Takaichi in push for Japan to retain R&D edge
- Penn Medicine, K Health partner to deploy AI clinical agents
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo
- CMS finalizes changes to No Surprises Act dispute resolution process
- Smartwatch App Accurately Detects Major Epileptic Seizures
- Racial Gap Exists For Asthma Inhaler Use
- New Colon Cancer Screening Guidelines Add Blood And At-Home Tests
- Fierce Pharma Asia—More China biotech hawkishness; Pfizer’s $10B Innovent deal; Astellas’ roadmap
- CVS expands partnership with Salesforce for greater call center personalization
- Nurse Convicted In Patient's Death Turns Fatal Drug Error Into Cautionary Tale
- Wearable Ultrasound Patch Monitors High-Risk Pregnancies In Real Time
- Listen to the Latest ‘KFF Health News Minute’
- In a Vaccine-Skeptical California County, a Potential Playbook To Contain Measles
- Teladoc Health inks partnership with Walmart to expand virtual care services
- PharmaEssentia taps Incyte alum Eric Vogel as it eyes Besremi expansion
- Kaléo speaks up on allergy awareness to amplify patient stories
- Privacy and PetShops: Remarks at the Regulatory PETshop Series: Cryptographic Technologies and Financial Services Regulation
- NYC Health + Hospitals adds 2nd behavioral health housing site
- Mindfulness isn’t a perk anymore — it’s a workforce strategy
- With Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
- Hospitals again ask FTC, DOJ for exemption from expanded premerger notification filings
- Coalition for Health AI unveils governance playbooks for responsible AI adoption
- Amazon taps Roy Schoenberg to lead healthcare business as Neil Lindsay plans to step down
- Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
- U.S. To Keep Ebola-Exposed Citizens In Kenya Under New Policy
- CAT on a Hot Tin Roof
- GLP-1 Meds May Help Slow the Spread of Certain Obesity-Related Cancers
- GoodRx launches subscription program for low-cost generic medications, telehealth services
- George Washington University locks deal to hand off debt-ridden physician practice to UHS
- Humana invests $83M in new Florida pharmacy distribution center
- As J&J separates from its orthopedics business, it's laying off 56 employees in New Jersey
- ASCO preview: With expectations jacked up, Akeso's ivonescimab to face scrutiny in high-stakes plenary
- An insider’s look at LillyDirect
- GLP-1 manufacturer CordenPharma strikes deal for peptide CDMO, lining up new production sites in US and China
- Weight-Loss Program Helps Women Battling Breast Cancer
- Younger U.S. Women of Color Face Rising Breast Cancer Deaths
- High Fitness Doesn’t Raise A-fib Risk In Young Men, Study Finds
- Cheaper, Alternative Health Plans Are Having A Moment, But Critics Urge Caution
- Ultrafine Wildfire Smoke Particles May Pose Serious Health Risks
- Montana Hurries To Adopt Trump’s Medicaid Work Rules Amid Budget Woes
- Readers Address Drugged Driving, Suicide Prevention, Worker Shortages
- Nurse Convicted in Patient’s Death Turns Fatal Drug Error Into a Cautionary Tale
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Amid policy and pricing headwinds, US healthcare and life sci faces 'vast field of opportunity': survey
- Biogen investigated by Italian regulator over multiple sclerosis ‘market abuse’ claims
- FDA delays ruling on AstraZeneca’s breast cancer drug after negative adcomm vote
- Eli Lilly wins argument over Noom’s GLP-1 dosing claims
- Remarks at the Stanford Rock Center for Corporate Governance
- Smart ring maker Oura files confidentially for IPO as consumer demand propels revenue growth
- Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
- JD Power: Cost pressures worsen member experience with commercial plans
- Trump Admin Bars Key U.S. Researchers From Global Virus Response Talk
- Listen to the Latest ‘KFF Health News Minute’
- As calls for COINS Act expansion grow, will new rules sweep up China biotech licensing?
- Everyone Has A Family Doc, But Can You Get An Appointment?
- Many U.S. College Students With Psychosis Are Not Receiving Treatment
- Antibiotics Won't Help Ease Asthma-Linked Wheezing in Kids
- Yoga Eases Insomnia And Anxiety In Cancer Survivors, Study Finds
- Dust Yields Clues to Viral Outbreaks, Study Finds
- 3 Medical Routines That Older People May Not Need
- Acting NIAID Chief Steps Down Amid Ebola, Hantavirus Concerns
- Sunscreen Confusion Puts More Americans At Risk For Melanoma
- 1 In 10 U.S. Surgeons Quit Practice, Study Warns Of Shortage
- Video Game Can Detect Depression In Minutes, Study Says
- Quitting Smoking Might Lower Your Dementia Risk
- Severe Asthma Often Comes With Other Serious Health Problems
- Efforts To Understand The Nation's Drugged Driving Problem Stall Under Trump
- RFK Jr. Fires Two Leaders Of Major U.S. Health Task Force
- Common Food Preservatives Linked to Major Heart Problems
- Migraine With Aura Linked To Middle-Age Stroke Risk
- Nicotine Vapes Triple Smokers' Odds Of Quitting Tobacco
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- Fixing Eligibility at the Point of Care: The Missing Link in Medical Device Reimbursement Integrity
- The failure of the ‘usual suspects’ approach to life science recruitment
- The failure of the ‘usual suspects’ approach to life science recruitment
- Statement on Novel Exchange-Traded Funds (ETFs)
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
- Value, Focus, and the Future of MedTech: M&A and Divestitures are Rewriting the Strategic Playbook.
People across the country are reporting illnesses after microdosing psilocybin with mushroom products from Diamond Shruumz of California. Microdosing involves taking very small doses of psychedelics in specially selected mushroom varieties, typically 10% to 20% of recreational doses.
The Michigan Department of Health and Human Services is warning Michigan's trend setters not to eat Diamond-Shruumz products. The U.S. FDA and Centers for Disease Control and Prevention are investigating illnesses associated with Diamond Shruumz-brand microdosing chocolate bars, infused cones, or microdose and macrodose gummies. The products are labeled as having a blend of mushroom varieties like Reishi and Lion's Mane. Their active ingredient, psilocybin is classified as a hallucinogen. Psilocybin used to cause all kinds of strange behaviors 50 years ago when it was a popular street drug.
Psilocybin mushrooms have been decriminalized in Ann Arbor and Detroit.
MDHHS alerting Michigan residents not to eat Diamond Shruumz-brand chocolate bars, cones and gummies during ongoing FDA investigation
By Lynn Sutfin - June 18, 2024LANSING, Mich.-The Michigan Department of Health and Human Services (MDHHS) and the Food and Drug Administration (FDA) are urging Michigan residents not to eat, sell or serve any flavor of Diamond Shruumz-brand Microdosing Chocolate Bars, Infused Cones or Micro Dose and Macro Dose gummies, and instead throw them away. The products are labeled as containing a proprietary blend of mushrooms such as reishi and lion’s mane.
“People in multiple states have become ill after eating these products, reporting a variety of severe symptoms,” said Dr. Natasha Bagdasarian, chief medical executive. “As these products look similar to candy, we urge parents and caregivers to consider discussing this information with their teens even though they are intended for individuals 18 and older. We are advising that everyone avoid these products.”
As of Friday, June 7, the FDA and Centers for Disease Control and Prevention (CDC), in collaboration with America’s Poison Centers and state and local partners, are investigating a series of illnesses associated with eating Diamond Shruumz-brand products. The FDA is working to determine the cause of these illnesses.
A total of 26 illnesses have been reported from 16 states, including Alabama, Arizona, California, Indiana, Kentucky, Maryland, Minnesota, Missouri, Montana, Nevada, New Jersey, New York, North Carolina, Pennsylvania, South Carolina and Tennessee. To date, there are no reported cases in Michigan.
Of those who became ill, 25 people reported seeking medical care, with 16 being hospitalized. No deaths have been reported. People who became ill from eating Diamond Shruumz-brand products reported a variety of severe symptoms including seizures, central nervous system depression (loss of consciousness, confusion, sleepiness), agitation, abnormal heart rates, hyper/hypotension, nausea and vomiting.
Diamond Shruumz-brand products can be purchased online or at a variety of retail locations nationwide, including smoke/vape shops or places that sell hemp-derived or CBD products.
Retailers should not sell or distribute any of these products. Instead, hold these products until further direction is given by the FDA.
Those who become ill after consuming these products should seek medical treatment. They can also call the Poison Help Line at 800-222-1222 to report symptoms and seek information. Callers should let Poison Control know they have recently consumed a Diamond Shruumz-brand chocolate bars, cone or gummies.
Health care providers should report these illnesses to their local health department or the Poison Help Line at 800-222-1222.
MDHHS will continue to monitor incoming information from FDA. Consumers and health care providers can monitor updates about this investigation at Investigation of Illnesses: Diamond Shruumz-Brand Chocolate Bars, Cones, & Gummies (June 2024) | FDA.
Physicians or residents with questions or concerns can contact MDHHS by calling 844-464-7327 or emailing mdhhs-eht@michigan.gov.
FDA is now investigating one death associated with these Diamond Shruumz microdose products, and it is now believed that the toxic agent which caused these sicknesses is muscimol not psilocybin:
https://www.upi.com/Health_News/2024/07/03/Diamond-Shruumz-death/5371719992921/
FDA probing death potentially linked to recalled microdosing candies
By Darryl Coote - July 3, 2024July 3 (UPI) -- Federal food safety officials are investigating a potential death linked to ingesting recalled microdosing chocolates and candies that have sickened dozens of people across the United States.
All Diamond Shruumz-brand chocolates and gummies were recalled late last month over the products containing toxic levels of muscimol, a chemical found in some mushrooms that can cause seizures, involuntary muscle contractions and a loss of consciousness, among other issues.
At least 48 illnesses linked to the edibles have been reported in 24 states as of Monday, the Food and Drug Administration said in an update to the recall on Tuesday.
Twenty-seven of the patients have been hospitalized, it said, adding that there is one potentially associated death under investigation.
American Poison Centers in a statement added that it has received 82 reports of exposure associated with the Diamond Shruumz products, including 48 cases of severe illness, of which all but two sought medical attention.
The FDA said those who became ill after eating Diamond Shruumz-brand products reported a variety of severe symptoms, including seizures, central nervous system depression, agitation, abnormal heart rates, nausea and vomiting.
Diamond Shruumz is instructing its customers to not eat their products amid the investigation. It said in a statment on its website that those who became ill from eating their products had consumed "the entire chocolate bar and some products containing higher levels of muscimol than normal."
The FDA is also recommending not to eat, sell or serve any flavor of Diamond Shruumz-brand chocolate bars, cones or gummies. Those in possession of the recalled products are being instructed to either discard them or return them to the company for a refund.
The products affected by the recall were sold online as well as at retail stores that sell such products, including smoke and vape shops.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.















